INmune Bio targets Ebstrocel U.K. MAA by end of Q3 or early Q4 2026 while outlining $1M-$1.5M monthly burn (NASDAQ:INMB)
· seekingalpha.com
INmune Bio (INMB) Q2 2026 earnings call: MHRA-aligned Ebstrocel MAA timeline, XPro Fast Track & MINDFuL MRI results, cash runway and burn.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...